Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioWa, a wholly owned subsidiary of Kyowa Hakko Kirin Co, has entered into a licensing agreement with CSL, an Australian biopharmaceutical company, providing CSL with access to BioWa's Potelligent Technology platform for the R&D of antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity.
Subscribe to our email newsletter
Under the license agreement, CSL will obtain non-exclusive rights to use Potelligent technology platform to research, develop, manufacture, and commercialize antibody-dependent cellular cytotoxicity (ADCC)-enhanced antibodies for an undisclosed number of targets.
In return, BioWa will receive upfront technology access fee, and may receive development milestone payments and royalties on products developed by CSL. Additional terms were not disclosed.
Potelligent Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. Potelligent Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout Chinese hamster ovary cell line as a production cell.
Masamichi Koike, president and CEO of BioWa, said: “We are very pleased to have this opportunity to work with CSL, our first Australian partner. We believe that CSL’s strength in biologics and significant presence in Australia and many other countries will help the technology to reach broader fields and territories.”